Bristol-Myers Squibb has ended a $3.1 billion strategic collaboration with Eisai focusing on antibody-drug conjugates (ADCs) and returned rights to the lead drug in the alliance.Eisai said in a statement published this morning that BMS’ reason for exiting the agreement was a “portfolio prioritisation effort”, but added that it intended to take over the development of the lead drug.
